This Week’s Biopharma News: ADCs, Biosimilars, and Microbiome Moves - Takeaways - MDSpire

This Week’s Biopharma News: ADCs, Biosimilars, and Microbiome Moves

  • May 26, 2026

Share

  • 1

    Merck's sacituzumab tirumotecan met phase 3 endpoints in advanced endometrial cancer, showing improved overall and progression-free survival.

  • 2

    Microbiotica's MB097, a microbiome therapy, demonstrated positive phase 1b results in advanced melanoma when combined with pembrolizumab.

  • 3

    Akeso's ligufalimab, an anti-CD47 monoclonal antibody, showed a survival signal in phase 2 trials for treatment-naïve acute myeloid leukemia.

  • 4

    Regeneron's phase 3 trial of fianlimab and cemiplimab in melanoma did not achieve statistical significance for progression-free survival.

  • 5

    The FDA finalized guidance on postapproval pregnancy safety studies to enhance safety data collection for drugs and biologics used during pregnancy.

Original Source(s)

This Week’s Biopharma News: ADCs, Biosimilars, and Microbiome Moves

  • May 26, 2026

Related Content

Beyond Nodule Detection: AI, Chest CT, and a Vision for Population Health

Lung cancer resulted in 1.8 million deaths globally in 2022 and remains the leading cause of cancer-related mortality worldwide. Low-dose CT screening has been shown to reduce lung cancer mortality, a...

Preclinical Study in Mice Addresses a Question: Should RAS Inhibitors Be Given Preemptively?

With recent data that RAS inhibition can improve survival in metastatic pancreatic cancer, the optimization of these agents has become a research priority. Minh Than, MD, PhD, a clinical and research ...

2026 NCCN Clinical Practice Guidelines in Oncology®: Key Updates Across Tumor Types

The National Comprehensive Cancer Network® (NCCN®) first introduced the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, initially covering eight tumor types. Three decades la...